Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries

Monika Słowińska1, Katarzyna Kotulska2, Sylwia Szymańska1

  • 1Department of Pediatric Neurology, Medical University of Warsaw, Warsaw, Poland.

Pediatric Neurology
|December 14, 2020
PubMed

Insights

Early EEG monitoring and preventive epilepsy treatment are increasingly adopted for infants with Tuberous Sclerosis Complex (TSC), despite limited trial data. This approach aims to improve epilepsy and neurodevelopmental outcomes in affected children.

Area of Science:

  • Neurology
  • Pediatrics
  • Epileptology

Background:

  • Tuberous Sclerosis Complex (TSC) significantly increases the risk of early-onset epilepsy and developmental delays in children.
  • Emerging strategies include EEG monitoring and preventive antiepileptogenic treatment to improve outcomes.

Purpose of the Study:

  • To investigate the impact of recent recommendations on epilepsy management practices for children with TSC.
  • To assess the current clinical adoption of EEG monitoring and preventive epilepsy treatment in infants with TSC.

Main Methods:

  • A global survey was distributed to 165 clinicians involved in TSC research (2016-2019).
  • Responses from 61 clinicians across 23 countries, providing neurological care for children with TSC, were analyzed.
  • Data collection included approaches to EEG monitoring and preventive epilepsy treatment.

Main Results:

  • 95% of surveyed clinicians perform pre-epilepsy onset EEG, and 70% conduct regular EEG monitoring.
  • Video EEG is the preferred method for monitoring in 68.8% of centers.
  • 51.7% of respondents endorse preventive antiepileptic treatment, with Vigabatrin being the preferred drug for infants under two years old.

Conclusions:

  • The principles of pre-epilepsy EEG monitoring and preventive epilepsy treatment are being implemented in most surveyed centers.
  • Clinical practice is evolving to incorporate these strategies for managing epilepsy in TSC, even without definitive randomized trial results.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
916
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
430
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
632
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
984
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.1K